Compare Accenture plc (ACN) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Accenture plc vs BridgeBio Pharma Inc — how do they compare? Accenture plc trades at $179.61 (market cap $109.08B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: Accenture plc is far larger — about 6.6× BridgeBio Pharma Inc's market cap, and Accenture plc pays a 3.66% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| ACN | BBIO | |
|---|---|---|
Market Cap | $109.08B | $16.61B |
Sector | Technology | Health |
52-Week High | $288.54 | $90.17 |
52-Week Low | $124.41 | $47.29 |
Enterprise Value | $107.30B | $18.16B |
Dividend Yield | 3.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $179.82, up 2.33% in the last session, with a bullish technical outlook and strong fundamental performance. The stock exhibits robust revenue growth, with 2025 revenue reaching $69.67 billion and net income of $7.68 billion, supported by consistent earnings beats. Recent partnerships with TEPCO Solution Advance and AlphaSense highlight strategic AI initiatives, enhancing its consulting and digital transformation services.
The investment outlook is positive, driven by solid financials, a consensus price target of $189.77, and low debt. Risks include competitive pressures and macroeconomic sensitivity. Analyst sentiment is strongly bullish with 66% buy ratings, indicating confidence in continued growth and shareholder value creation.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Accenture plc
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
